candesartan has been researched along with Brain Hemorrhage in 4 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Excerpt | Relevance | Reference |
---|---|---|
"The Scandinavian Candesartan Acute Stoke Trial was a randomized- and placebo-controlled trial of candesartan in 2,029 patients with acute stroke and systolic blood pressure ≥140 mmHg." | 9.20 | Effects of candesartan in acute stroke on vascular events during long-term follow-up: results from the Scandinavian Candesartan Acute Stroke Trial (SCAST). ( Bath, PM; Berge, E; Boysen, G; Hornslien, AG; Igland, J; Murray, GD; Sandset, EC; Terént, A, 2015) |
"The Scandinavian Candesartan Acute Stroke Trial (SCAST) indicated that blood pressure-lowering treatment with candesartan in the acute phase of stroke has a negative effect on functional outcome at 6 months, measured by the modified Rankin scale." | 9.20 | Effects of candesartan in acute stroke on activities of daily living and level of care at 6 months. ( Berge, E; Hornslien, AG; Sandset, EC; Wyller, TB, 2015) |
"SCAST was a randomized- and placebo-controlled, double-masked trial of candesartan given for 7 days, in 2029 patients with acute stroke and systolic blood pressure ≥140 mm Hg." | 9.19 | Blood pressure-lowering treatment with candesartan in patients with acute hemorrhagic stroke. ( Bath, PM; Berge, E; Jusufovic, M; Sandset, EC, 2014) |
"The Scandinavian Candesartan Acute Stroke Trial (SCAST) found no benefits of blood pressure-lowering treatment with candesartan in acute stroke." | 5.20 | Effects of blood pressure-lowering treatment in different subtypes of acute ischemic stroke. ( Bath, PM; Berge, E; Jusufovic, M; Sandset, EC; Sandset, PM, 2015) |
"The Scandinavian Candesartan Acute Stoke Trial was a randomized- and placebo-controlled trial of candesartan in 2,029 patients with acute stroke and systolic blood pressure ≥140 mmHg." | 5.20 | Effects of candesartan in acute stroke on vascular events during long-term follow-up: results from the Scandinavian Candesartan Acute Stroke Trial (SCAST). ( Bath, PM; Berge, E; Boysen, G; Hornslien, AG; Igland, J; Murray, GD; Sandset, EC; Terént, A, 2015) |
"The Scandinavian Candesartan Acute Stroke Trial (SCAST) indicated that blood pressure-lowering treatment with candesartan in the acute phase of stroke has a negative effect on functional outcome at 6 months, measured by the modified Rankin scale." | 5.20 | Effects of candesartan in acute stroke on activities of daily living and level of care at 6 months. ( Berge, E; Hornslien, AG; Sandset, EC; Wyller, TB, 2015) |
"SCAST was a randomized- and placebo-controlled, double-masked trial of candesartan given for 7 days, in 2029 patients with acute stroke and systolic blood pressure ≥140 mm Hg." | 5.19 | Blood pressure-lowering treatment with candesartan in patients with acute hemorrhagic stroke. ( Bath, PM; Berge, E; Jusufovic, M; Sandset, EC, 2014) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 4 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Jusufovic, M | 2 |
Sandset, EC | 4 |
Bath, PM | 3 |
Berge, E | 4 |
Sandset, PM | 1 |
Hornslien, AG | 2 |
Igland, J | 1 |
Terént, A | 1 |
Boysen, G | 1 |
Murray, GD | 1 |
Wyller, TB | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Scandinavian Candesartan Acute Stroke Trial[NCT00120003] | Phase 3 | 2,500 participants (Anticipated) | Interventional | 2005-06-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
4 trials available for candesartan and Brain Hemorrhage
Article | Year |
---|---|
Blood pressure-lowering treatment with candesartan in patients with acute hemorrhagic stroke.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Double-Blind Method; Female; Huma | 2014 |
Effects of blood pressure-lowering treatment in different subtypes of acute ischemic stroke.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Brain Ischemia; D | 2015 |
Effects of candesartan in acute stroke on vascular events during long-term follow-up: results from the Scandinavian Candesartan Acute Stroke Trial (SCAST).
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Brain Ischemia; F | 2015 |
Effects of candesartan in acute stroke on activities of daily living and level of care at 6 months.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biphen | 2015 |